Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)

Jan 29, 2018

Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

Jan 22, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

Jan 18, 2018

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018

Jan 8, 2018

Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer

Jan 4, 2018

Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium

Dec 11, 2017

Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

Nov 9, 2017

Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer

Nov 8, 2017

Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Nov 6, 2017

Rexahn Announces $8 Million Registered Direct Offering

Oct 13, 2017